Evaluation of clostridium novyi-NT spores in dogs with naturally occurring tumors

American Journal of Veterinary Research

Volumn 73, Issue 1, 2012, Pages 112-118

  Krick, Erika L ^a   Sorenmo, Karin U ^a   Rankin, Shelley C ^b   Cheong, Ian ^c   Kobrin, Barry ^c   Thornton, Katherine ^c   Kinzler, Kenneth W ^c   Vogelstein, Bert ^c   Zhou, Shibin ^c   Diaz, Luis A ^c  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLOSTRIDIUM NOVYI NT SPORE; UNCLASSIFIED DRUG;

ABSCESS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLOSTRIDIUM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; FUNGAL SPORE GERMINATION; INTOXICATION; NONHUMAN; NOSE CARCINOMA; SOLID TUMOR; SPLEEN ABSCESS; SPORE GERMINATION;

ANIMALIA; CANIS FAMILIARIS; CLOSTRIDIUM NOVYI;

EID: 84855275448     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.1.112     Document Type: Article

References (21)

1. Sturk C, Dumont D. Angiogenesis. In: Tannock IF, Hill RP, Bristow RG, et al, eds. The basic science of oncology. 4th ed. New York: McGraw-Hill, 2005:231-248.
2. Barbe S, Van Mellaert L, Anne J. The use of clostridial spores for cancer treatment. J Appl Microbiol 2006;101:571-578.
3. Torrey JC, Khan MC. The treatment of Flexner-Jobling rat carcinomas with bacterial proteolytic ferments. J Cancer Res 1927;11:334-376.
4. Connell H. The study and treatment of cancer by proteolytic enzymes. Can Med Assoc J 1935;33:364-370.
5. Parker RC, Plummer HC, Siebenmann CO, et al. Effects of histolyticus infections and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med 1947;66:461-465.
6. Malmgren RA, Flanigan CC. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 1955;15:743-748.
7. Mose JR, Mose G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other non-pathogenic clostridia against the Ehrlich carcinoma. Cancer Res 1964;24:212-216.
8. Thiele EH, Arison RN, Boxer GE. Oncolysis by clostridia III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 1964;24:222-233.
9. Schlechte H, Schwabe K, Mehnert WH, et al. Chemotherapy for tumours using clostridial oncolysis, antibiotics and cyclophosphamide: model trial on the UVT 15264 tumour. Arch Geschwulstforsch 1982;52:41-48.
10. Gericke D, Dietzel F, Ruster I. Further progress with oncolysis due to local high frequency hyperthermia, local x-irradiation and apathogenic clostridia. J Microw Power 1979;14:163-166.
11. Carey RW, Holland JF, Whang HY, et al. Clostridial oncolysis in man. Eur J Cancer 1967;3:37-46.
12. Heppner F, Mose JR. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir 1978;42:123-125.
13. Dang LH, Bettegowda C, Huso DL, et al. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001;98:15155-15160.
14. Diaz LA, Cheong I, Foss CA, et al. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci 2005;88:562-575.
15. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 2004;101:15172-15177.
16. Cheong I, Huang X, Bettegowda C, et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006;314:1308-1311.
17. Bettegowda C, Dang LH, Abrams R, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 2003;100:15083-15088.
18. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147-156.
19. Veterinary Co-operative Oncology Group. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. A consensus statement from the Veterinary Co-operative Oncology Group. Vet Comp Oncol 2004;2:194-213.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
21. Turek MM, Withrow SJ. Perianal tumors. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's small animal clinical oncology. 4th ed. Philadelphia: Saunders, 2007;503-510.